DekaBank Deutsche Girozentrale’s Recursion Pharmaceuticals RXRX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-60,000	Closed	-$387K	–	1310
2023 Q1	$387K	Hold	60,000	–	–	﹤0.01%	1062
2022 Q4	$460K	Hold	60,000	–	–	﹤0.01%	1055
2022 Q3	$651K	Buy	60,000 +21,500	+56%	+$218K	﹤0.01%	989
2022 Q2	$310K	Buy	+38,500	New	+$258K	﹤0.01%	1116
2022 Q1	–	Sell	-35,000	Closed	-$592K	–	1425
2021 Q4	$592K	Buy	+35,000	New	+$659K	﹤0.01%	1061

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RXRX Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 60,000 shares — an estimated $387K sold.

DekaBank Deutsche Girozentrale first reported a position in RXRX in Q4 2021 and held it in 5 quarters. The position peaked at $651K in Q3 2022. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 60,000 Recursion Pharmaceuticals shares in Q2 2023, an estimated $387K.
DekaBank Deutsche Girozentrale first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 5 quarters.
DekaBank Deutsche Girozentrale's Recursion Pharmaceuticals position peaked at $651K in Q3 2022.
158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.